Literature DB >> 28940326

Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.

Partha Basu1, Antonio Ponti2, Ahti Anttila3, Guglielmo Ronco2, Carlo Senore2, Diama Bhadra Vale4, Nereo Segnan2, Mariano Tomatis2, Isabelle Soerjomataram5, Maja Primic Žakelj6, Joakim Dillner7, Klara Miriam Elfström8, Stefan Lönnberg9, Rengaswamy Sankaranarayanan1.   

Abstract

The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring (N = 80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population-based approach was documented. Among the age-eligible women, 94.7% were residents of Member States implementing or planning population-based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll-out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population-based screening increased to 72.4% of the age-eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2-111% for breast cancer, 7.6-105% for cervical cancer and 1.8-127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes.
© 2017 UICC.

Entities:  

Keywords:  European Union; breast cancer; cancer screening; cervical cancer; colorectal cancer

Mesh:

Year:  2017        PMID: 28940326     DOI: 10.1002/ijc.31043

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

Review 1.  The narrow path to organized LDCT lung cancer screening programs in Europe.

Authors:  Eugenio Paci
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Programmed colorectal cancer screening decreases incidence and mortality.

Authors:  Susana Roselló; Soraya Simón; Andrés Cervantes
Journal:  Transl Gastroenterol Hepatol       Date:  2019-12-26

Review 3.  False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health.

Authors:  Anna Macios; Andrzej Nowakowski
Journal:  Diagnostics (Basel)       Date:  2022-06-20

4.  The efficiency of public policies and programs for breast cancer prevention. Socio-medical perspectives within a Romania-France comparison.

Authors:  Gabriela Motoi; Andreea Mihaela Niţă
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

5.  Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions.

Authors:  Gonçalo Forjaz de Lacerda; Scott P Kelly; Joana Bastos; Clara Castro; Alexandra Mayer; Angela B Mariotto; William F Anderson
Journal:  Cancer Epidemiol       Date:  2018-03-13       Impact factor: 2.984

6.  Immunomagnetic bead-based bioassay for the voltammetric analysis of the breast cancer biomarker HER2-ECD and tumour cells using quantum dots as detection labels.

Authors:  Maria Freitas; Henri P A Nouws; Elisa Keating; Virginia Cruz Fernandes; Cristina Delerue-Matos
Journal:  Mikrochim Acta       Date:  2020-02-22       Impact factor: 5.833

7.  Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.

Authors:  Anja Oštrbenk; Lan Xu; Marc Arbyn; Mario Poljak
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

Review 8.  An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer.

Authors:  Andrea N Burnett-Hartman; Jeffrey K Lee; Joshua Demb; Samir Gupta
Journal:  Gastroenterology       Date:  2021-01-05       Impact factor: 22.682

9.  Clinical and health policy experiences with HPV prevalence within the Hungarian organized cervical cancer screening program.

Authors:  Réka Vajda; Krisztina Juhász; Dóra Endrei
Journal:  J Gynecol Oncol       Date:  2018-03-01       Impact factor: 4.401

10.  Association between age factors and strategies for promoting participation in gastric and colorectal cancer screenings.

Authors:  Chisato Hamashima; Hiroshi Sano
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.